Opinion

Video

The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
4 experts in this video
4 experts in this video
Related Content
BRCA | Image Credit: syahrir - stock.adobe.com
September 5th 2025

Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing

Brooke McCormick
managed care cast logo
September 5th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM
Molecular structure of INSTI | Image credit: Сергей Шиманович - stock.adobe.com
September 5th 2025

ACC017 Showed Safety, Tolerability When Used as Antiretroviral Therapy

Julia Bonavitacola
managed care cast logo
September 5th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
Cell and gene therapies | Image Credit: © ArtemisDiana-stock.adobe.com
September 5th 2025

RNA CAR T Shows Promise for Myasthenia Gravis

Maggie L. Shaw
HIV test | Image credit: gamjai - stock.adobe.com
September 5th 2025

Cotesting for HIV, STIs Improved Screening Practices for HIV

Julia Bonavitacola

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo